Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

HUMIRA sales drive growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
 
1Q Revenues: $4.6 billion (+5%)

1Q Earnings: $980 million (+1%)

Comments: Growth in the quarter was primarily driven by HUMIRA sales, up 18% to $2.6 billion, as well as key products including Synthroid (up 31% to $157 million), Creon (up 18% to $107 million) and Duodopa (up 32% to $52 million).Synagis sales were $324 million, up 3%. AndroGel sales were $254 million, up 6%. Kaletra sales were down 11% to $195 million. Niaspan and TriCor/Trilipix dropped 75% and 82% to $47 and $23 million, respectively, due to patent expiries. The company recently submitted its U.S. regulatory application for its interferon-free regimen for hepatitis C virus (HCV), and plans additional applications in the EU. The company expects U.S. commercialization in 2014 and European approval in early 2015.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters